Systematic review finds epinephrine shows potential in treating no-reflow, suggesting therapeutic value in severe cases.
Therefore, intracoronary epinephrine was associated with encouraging but exploratory findings, and the higher success rate in primary no-reflow may reflect earlier intervention and less severe microvascular damage. Its modest advantage over adenosine suggests potential therapeutic value, though evidence remains limited and heterogeneous.
No takes yet. Share an insight, caveat, or question.
SILVA et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: